このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

明細胞卵巣がんにおけるペムブロリズマブとレンバチニブ

2026年11月3日 更新者:Elizabeth K. Lee MD

再発性または持続性の卵巣明細胞癌患者におけるペムブロリズマブとレンバチニブの第II相試験

This research study is being done to test the efficacy and safety of combining the study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer.

The names of the study drugs involved in this study are:

  • Lenvatinib
  • Pembrolizumab

調査の概要

状態

積極的、募集していない

詳細な説明

This is an open label, non-randomized, single cohort phase II trial. Participants with recurrent or persistent clear cell ovarian carcinoma (CCOC) will be treated with the investigational combination of pembrolizumab and lenvatinib until progression of disease or unacceptable toxicity.

The names of the study drugs involved in this study are:

  • Lenvatinib
  • Pembrolizumab

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

Participants will receive study treatment until progression of disease or unacceptable toxicity. Participants will be followed for 36 months thereafter. It is expected that about 31 people will take part in this research study.

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drugs work in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved lenvatinib or pembrolizumab for your specific disease but it has been approved for other uses.

研究の種類

介入

入学 (実際)

30

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Illinois
      • Chicago、Illinois、アメリカ、60637
        • University of Chicago Medicine
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02115
        • Dana Farber Cancer Institute
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • Mayo Clinic Comprehensive Cancer Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  • Participants must have histologically or cytologically confirmed recurrent or persistent clear cell carcinoma of the ovary (CCOC) (≥50% clear cell histology).

  • Participants must have measurable disease, defined as at least one lesion that can be accurately measured per RECIST v1.1 criteria. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

  • Participants must have received at least one prior platinum-based chemotherapeutic regimen for primary management of disease.

  • Prior bevacizumab is allowed.

  • Prior use of immune checkpoint inhibitors (e.g. anti-PD-1, anti-PD-L1, anti-CTLA-4) is allowed for up to 30% of participants.

  • Unlimited prior lines for the treatment of recurrent or persistent disease are allowed.

  • Age ≥18 years. Because no dosing or adverse event data are currently available on the use of the combination of pembrolizumab/lenvatinib in participants <18 years of age, children are excluded from this study.

  • ECOG performance status of 0 or 1 (Karnofsky performance scale ≥70%).

  • Participants must have adequate organ and marrow function as defined below:

    • absolute neutrophil count ≥1,500/μcL
    • hemoglobin ≥ 9g/dL (without use of erythropoietin; without packed RBC transfusion within preceding 2 weeks)
    • platelet count ≥100,000/μcL
    • total bilirubin ≤ institutional upper limit of normal (ULN) (in the absence of liver metastases) or ≤ 1.5 × institutional ULN (in the presence of liver metastases)
    • AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN (in the absence of liver metastases) or ≤5 × institutional ULN (in the presence of liver metastases)
    • creatinine ≤ 1.5 ×ULN OR glomerular filtration rate (GFR) ≥30mL/min per the CKD-EPI formula for participants with Cr >1.5×ULN. The CKD-EPI formula is calculated as: GFR = 141 × min (Scr /κ, 1)α × max(Scr /κ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if black] here: Scr is serum creatinine in mg/dL, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr /κ or 1, and max indicates the maximum of Scr /κ or 1.
    • PT/INR, aPTT ≤ 1.5x ULN unless participant is receiving anticoagulant therapy and the PT/INR or aPTT is within the intended therapeutic range of the anticoagulant
  • Participants must have adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as a BP ≤ 140/90 at screening and no change in antihypertensive medications within 2 weeks prior to Cycle 1 Day 1.

  • Participants with known brain metastases are eligible if they have completed primary CNS-directed therapy (such as surgical resection or radiotherapy) and if they have remained clinically stable, asymptomatic, radiologically stable without evidence of progression for at least 4 weeks by repeat imaging, and have been off of steroids for at least 4 weeks prior to starting study treatment.

  • Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen, as determined after discussion with the PI, are eligible for this trial.

  • Archival tumor tissue must be available as 27 (25 unstained + 2 H&E) freshly serially cut slides from formalin-fixed, paraffin-embedded (FFPE) tissue blocks. The most recent available tissue is preferred to archived tissue. If fewer than 27 slides are available, the participant may still be eligible pending discussion with the Sponsor-Investigator.

  • The effects of pembrolizumab and lenvatinib on the developing human fetus are unknown. For this reason and because these agents are known to be teratogenic, women of child-bearing potential* must have a negative serum or urine pregnancy test at the Screening and Cycle 1 Day 1 visits. Women of child-bearing potential and men must agree to use adequate contraception (see Appendix D) prior to study entry, for the duration of study participation, and for at least 30 days after last receipt of study therapy. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.

    -- Female participants are NOT considered to be of childbearing potential if they meet either criteria: (1) Post-menopausal, defined as amenorrheic for at least 12 consecutive months within the appropriate age group and without an alternative medical cause, OR; (2) Surgically sterilized (i.e. bilateral oophorectomy, bilateral tubal ligation or salpingectomy, or total hysterectomy)

  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  • Prior use of lenvatinib.
  • Use of any immunosuppressive therapy, including steroids used for the purpose of systemic immunosuppression (with dosing exceeding 10mg daily of prednisone or equivalent), within 2 weeks prior to beginning study treatment. The use of steroids as physiologic replacement (e.g. for adrenal or pituitary insufficiency) is allowed. The use of inhaled steroids (e.g. for the treatment of asthma or seasonal allergies) is allowed. The use of prophylactic corticosteroids to avoid allergic reactions (e.g. to IV contrast dye) is allowed.
  • Anti-cancer treatment (chemotherapy, radiotherapy, or other investigational therapy) within 4 weeks prior to entering the study (6 weeks prior to study entry for nitrosoureas or mitomycin C).
  • Prior radiation therapy within 2 weeks of start of study drugs. Participants must have recovered from all radiation-related toxicities and must not require steroids. Participants must not have had radiation pneumonitis. Palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease is permitted, provided there is at least a 1-week washout prior to start of study drugs.
  • Use of herbal supplements, including but not limited to: cannabis, St. John's wort, gingko biloba, ginseng, saw palmetto, and ephedra. Herbal supplements must be stopped at least 1 week prior to beginning study treatment.
  • Residual toxicities from prior anti-cancer therapy that remain Grade > 1, with the exception of alopecia and peripheral neuropathy. Toxicities related to prior treatments must have resolved to Grade ≤1 to be eligible.
  • Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines are allowed.
  • Major surgical procedures within 4 weeks of beginning study treatment are not allowed. Minor surgical procedures (with the exception of port placement) within 1 week of beginning study treatment are not allowed.
  • Subjects having >1+ proteinuria on urinalysis must undergo a 24-hour urine collection for quantitative assessment of proteinuria. Subjects with urine protein ≥1g/24 hours will be ineligible.
  • Evidence of bowel involvement.
  • Any gastrointestinal disorder that would interfere with the passage or absorption of oral medications. Participants must be able to swallow oral medications. Participants with an enteric tube (e.g. gastrostomy or jejunostomy tube), receiving total parenteral nutrition (TPN), or dependent on IV fluid support are ineligible.
  • Participants with significant cardiovascular impairment, including uncontrolled hypertension, congestive heart failure of New York Heart Association Grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia within the past 6 months.
  • Resting corrected QT interval (QTc) interval using the Fridericia formula (QTcF) >450 ms for males or >470 ms for females."
  • Clinically significant bleeding within 4 weeks of beginning study treatment.
  • Active autoimmune disease requiring systemic treatment (e.g. use of steroids, immunosuppressive medications, or disease modifying agents) within the past 2 years.
  • Has a diagnosis of immunodeficiency.
  • Is known to be positive for Human Immunodeficiency Virus (HIV). Subjects with HIV, including those on antiretroviral therapy, are excluded due to risk of immunodeficiency and risk of overlapping hepatotoxicity between antiretroviral agents and lenvatinib.
  • Is known to be positive for Hepatitis B virus (HBV) or Hepatitis C virus (HCV). Participants are eligible if they have a history of HCV infection that has been treated and cured, with an undetectable viral load.
  • History of allogeneic tissue/solid organ transplant.
  • History of non-infectious pneumonitis/interstitial lung disease that required steroids, or has current pneumonitis/interstitial lung disease.
  • Participants with uncontrolled intercurrent illness, including but not limited to active infection and serious non-healing wounds or ulcers.
  • Participants with psychiatric illness/social situations that would limit compliance with study requirements.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenvatinib, pembrolizumab, or any of the study drug excipients.
  • Pregnant women are excluded from this study because pembrolizumab and/or lenvatinib are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pembrolizumab and/or lenvatinib, breastfeeding should be discontinued if the mother is treated with either agent.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:PEMBROLIZUMAB and LENVATINIB

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

The names of the study drugs involved in this study are:

  • Lenvatinib
  • Pembrolizumab

Treatment will continue until progression of disease or unacceptable toxicity. Participants will be followed for up to 36 months after discontinuation of study treatment.

Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.

他の名前:
  • レンビマ
  • レンバチニブメシル酸塩

Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.

Pembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment ("Pembrolizumab Re-Treatment") if they progress after stopping pembrolizumab and while receiving lenvatinib.

他の名前:
  • キイトルーダ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Overall Response Rate (ORR)
時間枠:ORR expected to be observed up to 3 years

The objective response rate (ORR) is defined as the proportion of participants achieving a complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment.

ORR expected to be observed up to 3 years
6 Month Progression-free survival (PFS) Rate
時間枠:Disease will be evaluated at baseline and every 3 cycles on treatment, where each cycle is 3 weeks. Relevant to this endpoint is the 6 month timepoint.

6-month PFS rate is the proportion of participants who are alive and progression-free at 6 months. Progression-free survival (PFS) based on the Kaplan-Meier method is defined as the duration of time from study entry to documented disease progression (PD) or death.

Disease will be evaluated at baseline and every 3 cycles on treatment, where each cycle is 3 weeks. Relevant to this endpoint is the 6 month timepoint.

二次結果の測定

結果測定
メジャーの説明
時間枠
Grade 3 or Higher Treatment-Related Toxicity Rate
時間枠:AEs expected to be observed up to 3 years

All grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 as reported on case report forms are counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation.

AEs expected to be observed up to 3 years
Median Progression-free survival (PFS)
時間枠:Disease is evaluated at baseline, every 3 cycles on treatment (each cycle is 3 weeks), and in follow-up every 6 months (off due to PD) or every 3 months (off not due to PD), up to 3 years.

Median PFS based on the Kaplan-Meier method is defined as the median duration of time from study entry to documented disease progression (PD) or death.

Disease is evaluated at baseline, every 3 cycles on treatment (each cycle is 3 weeks), and in follow-up every 6 months (off due to PD) or every 3 months (off not due to PD), up to 3 years.
Clinical Benefit Rate (CBR)
時間枠:Disease will be evaluated every 3 cycles on treatment (each cycle is 3 weeks); Treatment continues until disease progression or unacceptable toxicity. Treatment duration is expected to be up to 3 years.

CBR is defined as the proportion of participants with Partial Response (PR) + Complete Response (CR) + Stable Disease (SD) ≥6 months per RECIST 1.1. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Disease will be evaluated every 3 cycles on treatment (each cycle is 3 weeks); Treatment continues until disease progression or unacceptable toxicity. Treatment duration is expected to be up to 3 years.
Median Overall Survival (OS)
時間枠:Survival is evaluated in follow-up every 6 months (off due to PD) or every 3 months (off not due to PD), up to 3 years.

OS based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive.

Survival is evaluated in follow-up every 6 months (off due to PD) or every 3 months (off not due to PD), up to 3 years.
ORR by PD-L1 expression status
時間枠:ORR is expected to be observed up to 3 years

PD-L1 expression at baseline is dichotomized as positive or negative per established scoring methods. ORR within PD-L1 expression status groups is the proportion of participants achieving CR + PR per RECIST 1.1 on treatment.

ORR is expected to be observed up to 3 years
[immune RECIST] Objective Response Rate (ORR)
時間枠:[immune RECIST] ORR is expected to be observed up to 3 years

The objective response rate (ORR) is defined as the proportion of participants achieving complete response (iCR) or partial response (iPR) per immune-RECIST (iRECIST).

[immune RECIST] ORR is expected to be observed up to 3 years
[immune RECIST] 6 Month Progression-free survival (PFS) Rate
時間枠:Disease will be evaluated at baseline and every 3 cycles on treatment, where each cycle is 3 weeks. Relevant to this endpoint is the 6 month timepoint.

6-month PFS rate is the proportion of participants who are alive and progression-free at 6 months. Progression-free survival based on the Kaplan-Meier method is defined as the duration of time from study entry to documented disease progression (PD) or death, per immune-RECIST 1.1 (iRECIST) criteria.

Disease will be evaluated at baseline and every 3 cycles on treatment, where each cycle is 3 weeks. Relevant to this endpoint is the 6 month timepoint.
[immune RECIST] Median Progression-free Survival (PFS)
時間枠:Disease is evaluated at baseline, every 3 cycles on treatment, and in follow-up every 6 months (off due to PD) or every 3 months (off not due to PD), up to 3 years

Progression-free survival based on the Kaplan-Meier method is defined as the duration of time from study entry to documented disease progression (PD) per immune-RECIST (iRECIST) or death.

Disease is evaluated at baseline, every 3 cycles on treatment, and in follow-up every 6 months (off due to PD) or every 3 months (off not due to PD), up to 3 years
[immune RECIST] Median Overall Survival (OS)
時間枠:Survival is evaluated in follow-up every 6 months (off due to PD) or every 3 months (off not due to PD), up to 3 years.

OS based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive per immune-RECIST (iRECIST).

Survival is evaluated in follow-up every 6 months (off due to PD) or every 3 months (off not due to PD), up to 3 years.
[immune RECIST] clinical benefit rate (CBR)
時間枠:Disease will be evaluated every 3 cycles on treatment; Treatment is continued until disease progression or unacceptable toxicity. Treatment duration is expected to be up to 3 years.

CBR is defined as Partial Response (iPR) + Complete Response (iCR) + Stable Disease (iSD) ≥6 months per immune -ECIST (iRECIST).

Disease will be evaluated every 3 cycles on treatment; Treatment is continued until disease progression or unacceptable toxicity. Treatment duration is expected to be up to 3 years.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Elizabeth K Lee, MD、Dana-Farber Cancer Institute

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年9月23日

一次修了 (実際)

2026年9月8日

研究の完了 (推定)

2028年11月15日

試験登録日

最初に提出

2022年3月16日

QC基準を満たした最初の提出物

2022年3月16日

最初の投稿 (実際)

2022年3月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月3日

最終確認日

2025年12月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 21-739

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD 共有時間枠

Data can be shared no earlier than 1 year following the date of publication

IPD 共有アクセス基準

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する